



World Headquarters
1025 Connecticut Ave. NW
Suite 717
Washington, DC 20036
Phone: 202.965.2288
www.RxBioSci.com

London
One Northumberland Avenue
Trafalgar Square
London WC2N 5BW

Hong Kong
Suites 2207-2209
Tower Two, Lippo Centre
89 Queensway, Admiralty
Hong Kong

MEDIA RELEASE

FOR IMMEDIATE RELEASE

Contact

Christos Efessiou, PhD
Phone: 202.965.2288
Email: cefessiou@RxBioSci.com

Clinical data shows MucoAd™ may offer significant benefits for patients suffering from dry eye syndrome, improving drug delivery to the conjunctival sack in the treatment of conditions such as allergic conjunctivitis

Philadelphia, PA - March 19, 2008 MucoAd™, a mucoadhesive pharmaceutical agent, delayed tear clearance in human subjects in a double-blind study presented today at the American Academy of Allergy, Asthma and Immunology (AAAAI) in Philadelphia.

According to researchers at [Strategic BioSciences](http://www.RxBioSci.com) who presented the data, the results could have important implications for patients suffering from dry eye syndrome and for improving drug delivery to the conjunctival sack in the treatment of conditions such as allergic conjunctivitis.

MucoAd™ is a patented non-toxic, non-irritating, liquid polymer mucoadhesive carrier that prolongs the contact time between drug and mucosa, thus increasing bioavailability and efficacy of the delivered drug. It can be “loaded” with nearly any pharmaceutical preparation and delivered a variety of mucosal tissues. The adherence of pharmaceuticals to the mucosa may permit lower doses of the administered drug so that the desired therapeutic affect could be achieved with fewer adverse reactions. In the study presented, tear clearance was significantly slower with a MucoAd™- fluorescein solution compared to standard, diagnostic fluorescein. The MucoAd™ solution was also better tolerated: overall, subjects reported no unpleasant sensations.

[Strategic BioSciences](http://www.RxBioSci.com), a specialty pharmaceutical company, is now developing the methods and technology to assess and adjust the required mucoadhesive properties for several specific medications. Thus far, researchers have shown that using MucoAd™ with a decongestant preparation of xylometazoline 0.1% increased clinical efficacy as compared to the standard decongestant spray while also decreasing rebound swelling and other side effects. MucoAd™ is also being used to develop a stable intranasal solution of the antihistamine loratadine, commonly known as Claritin® or Alavert®, which formerly was practically insoluble. A topical nasal formulation of the anti-emetic agent metoclopramide is also in development.

Dr. Christos S. Efessiou, Strategic BioSciences Chief Executive Officer, commented, “The delay of tear clearance and the absence of side effects demonstrated by MucoAd™ in this study, underscores the technology’s position in the New Frontier of drug delivery. We are excited at the possibilities MucoAd™ offers in the administration of medications which up to now could only be delivered by injection such as insulin and epinephrine.”

Neil White, Director of Fortune Apex Development said, “Strategic BioSciences represents a significant step towards developing the applications, for our unique, patented technology, which in addition to clinical advantages, offers MucoAd™ licensees significant opportunities for patent extensions.”

Strategic Pharmaceuticals Company, doing business as Strategic BioSciences, is a District of Columbia based pharmaceutical company. It is the joint venture of SRxA Holdings Inc, an affiliate of [Strategic Pharmaceutical Advisors](http://www.StrategicPharmaceuticalAdvisors.com) of Washington, DC and [Fortune Apex Development](http://www.FortuneApexDevelopment.com) of Hong Kong. Strategic BioSciences holds the exclusive global rights to MucoAd™.